Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage.
Lizzo G, Migliavacca E, Lamers D, Frézal A, Corthesy J, Vinyes-Parès G, Bosco N, Karagounis LG, Hövelmann U, Heise T, von Eynatten M, Gut P. Lizzo G, et al. Among authors: von eynatten m. Front Aging. 2022 Mar 7;3:852569. doi: 10.3389/fragi.2022.852569. eCollection 2022. Front Aging. 2022. PMID: 35821844 Free PMC article.
Letter to the editor regarding: "Pharmacokinetics of teneligliptin in subjects with renal impairment." Halabi et al., Clinical Pharmacology in Drug Development 2013;2:246-254.
Graefe-Mody U, Friedrich C, von Eynatten M, Thiemann S, Heise T, Woerle HJ. Graefe-Mody U, et al. Among authors: von eynatten m. Clin Pharmacol Drug Dev. 2014 Sep;3(5):417-8. doi: 10.1002/cpdd.119. Epub 2014 May 26. Clin Pharmacol Drug Dev. 2014. PMID: 27129015 No abstract available.
Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials.
Davidson JA, Lajara R, Aguilar RB, Mattheus M, Woerle HJ, von Eynatten M. Davidson JA, et al. Among authors: von eynatten m. BMJ Open Diabetes Res Care. 2014 Apr 16;2(1):e000020. doi: 10.1136/bmjdrc-2014-000020. eCollection 2014. BMJ Open Diabetes Res Care. 2014. PMID: 25452864 Free PMC article.
Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial.
Laakso M, Rosenstock J, Groop PH, Barnett AH, Gallwitz B, Hehnke U, Tamminen I, Patel S, von Eynatten M, Woerle HJ. Laakso M, et al. Among authors: von eynatten m. Diabetes Care. 2015 Feb;38(2):e15-7. doi: 10.2337/dc14-1684. Diabetes Care. 2015. PMID: 25614693 Clinical Trial. No abstract available.
Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
Cooper ME, Perkovic V, McGill JB, Groop PH, Wanner C, Rosenstock J, Hehnke U, Woerle HJ, von Eynatten M. Cooper ME, et al. Among authors: von eynatten m. Am J Kidney Dis. 2015 Sep;66(3):441-9. doi: 10.1053/j.ajkd.2015.03.024. Epub 2015 May 7. Am J Kidney Dis. 2015. PMID: 25960304 Free article.
133 results